Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nrx Pharmaceuticals Inc (NQ: NRXP )

1.230 +0.020 (+1.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nrx Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Jonathan Javitt, CEO of NRx Pharmaceuticals Inc. (NASDAQ: NRXP), to Present at NobleCon20
Via Investor Brand Network
HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), 
Via Benzinga
Plans for New Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression and Related Disorders: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Regulatory Compliance
Exposures Legal Regulatory
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Regulatory Compliance Retirement
Exposures Legal Pension Regulatory
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q2 2024
NRXP stock results show that NRX Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Alignment with FDA on Pediatric Study Plan and Accelerated Approval to Treat Bipolar Depression and Akathisia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Exposures Product Safety
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to... 
Via PRLog
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Accelerated Approval to Treat Bipolar Depression and Akathisia Could Yield Over $150 in Revenue Per Share; Planned HOPE Subsidiary Spinoff to Continue: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant’s Efficacy in Reducing Suicidality in Bipolar Depression at ASCP June 2024 Meeting: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
First Oral Antidepressant Clinically Demonstrated to Reduce Suicidality in Bipolar Depression with Data Supporting Accelerated Approval Process: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024
NRXP stock results show that NRX Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update
Via ACCESSWIRE
Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plans to Seek Accelerated Approval for Bipolar Depression and Schizophrenia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Gold Down Over 2%; 3M Profit Beats Expectations
Via Benzinga
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study
NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression. 
Via Benzinga
InvestorNewsBreaks – NRx Pharmaceuticals Inc. Releases Pricing of Public Offering, Expected to Result in Estimated $2M
Via Investor Brand Network
Exposures Product Safety
Nasdaq Down 0.5%; Lithium Americas Shares Slide
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Is Bio-Path (BPTH) Stock Up 89% Today?
Bio-Path stock is up with heavy trading of BPTH shares today alongside positive news from its ongoing clinical trial of BP1002. 
Via InvestorPlace
Why Is AGBA Group (AGBA) Stock Up 149% Today?
AGBA Group stock is rising higher on Thursday after the company announced plans to combine with Triller to create a $4 billion entity. 
Via InvestorPlace
Dow Surges Over 100 Points; D.R. Horton Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 37,880.89 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?
NRX Pharmaceuticals stock is down on Thursday after the company announced a public offering for NRXP shares after just avoiding delisting. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.